Publication Name	World Journal of Gastroenterology
Manuscript ID	40896
Country	Japan

Received	2018-07-17 07:07
Peer-Review Started	2018-07-17 07:40
To Make the First Decision	2018-07-25 01:02
Return for Revision	2018-07-25 03:00
Revised	2018-08-02 10:41
Second Decision	2018-08-20 08:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-08-24 09:05
Articles in Press	2018-08-24 09:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-10-04 02:02
Publish the Manuscript Online	2018-10-12 05:32

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
Manuscript Source	Invited Manuscript
All Author List	Ken Sato and Toshio Uraoka
ORCID	Author(s) ORCID Number Ken Sato http://orcid.org/0000-0002-3202-7983 Toshio Uraoka http://orcid.org/0000-0002-4425-4331
Funding Agency and Grant Number
Corresponding Author	Ken Sato, MD, PhD, Associate Professor, Doctor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp
Key Words	Chronic hepatitis C; Direct-acting antivirals; Resistant-associated substitution; P32 deletion; Non­structural protein 5A
Core Tip	P32 deletion, as a nonstructural protein 5A resistance-associated substitution (RAS), has been gradually noticed in patients who experience treatment failure associated with daclatasvir and asunaprevir as an antiviral therapy for chronic hepatitis C. Information regarding P32 deletion is very limited at the present. Although the prevalence of this RAS is assumed to be low, it was found to be a new threat to current direct-acting antiviral-based combination therapy. There is an urgent need for further basic and clinical studies on this RAS. Exploring and overcoming this RAS is essential for antiviral therapy for chronic hepatitis C.
Publish Date	2018-10-12 05:32
Citation	Sato K, Uraoka T. challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World J Gastroenterol 2018; 24(38): 4304-4310
URL	http://www.wjgnet.com/1007-9327/full/v24/i38/4304.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i38.4304

Full Article (PDF)	WJG-24-4304.pdf
Manuscript File	40896-Review.docx
Answering Reviewers	40896-Answering reviewers.pdf
Audio Core Tip	40896-Audio core tip.MP3
Conflict-of-Interest Disclosure Form	40896-Conflict-of-interest statement.pdf
Copyright License Agreement	40896-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	40896-Language certificate.pdf
Peer-review Report	40896-Peer-review(s).pdf
Scientific Misconduct Check	40896-Scientific misconduct check.pdf
Scientific Editor Work List	40896-Scientific editor work list.pdf